Pipeline

R&D is the core of our innovation. Sinotau has expanded product portfolio into oncology, cardiology and neurology with a diverse and competitive range of radiopharmaceutical pipelines. All with the mission of inventing radiopharmaceuticals for lives.

Diagnostic
Therapeutic

Cardiovascular disease

Pipeline
Pre-clinical
During clinical
NDA(ANDA)

XTR003

Detection of myocardial viability/metabolism

XTR004

Detection of myocardial ischemia

Neurodegenerative disease

Pipeline
Pre-clinical
During clinical
NDA(ANDA)

XTR006

AD

Cancer

Pipeline
Pre-clinical
During clinical
NDA(ANDA)

XTR008

Neuroendocrine tumor

XTR015

NETs

XTR024

G1/G2 GEP-NETs with Lu-SSTR treated/G3 NETs/NECs;Breast cancer;ES-SCLC

XTR010

Prostate cancer

XTR020

Prostate cancer

XTR021

mCRPC

XTR022

mCRPC that have failed 177Lu-PSMA treatment;mCRPC (≥2L)

XTR012

mCRPC, symptomatic bone metastases and no known visceral metastases

XTR025

Glioblastoma